Skip to main content

Table 3 Tissue weight of rats fed HC diets and treated with doses of β-conglycinin, fenofibrate, rosuvastatin and mixtures

From: β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats

  Dietary groups1
  HC HC+7S HC+FF HC+RO HC+7S+FF HC+7S+RO
Liver weight (g/rat) 13.54 ± 0.36 13.55 ± 0.87 21.10 ± 0.69** 17.07 ± 0.92* 19.32 ± 0.38** 12.83 ± 0.51
Heart (g/rat) 1.03 ± 0.04 0.94 ± 0.03 0.95 ± 0.03 1.26 ± 0.05 0.96 ± 0.02 0.89 ± 0.05
Hepatossomatic índex* (HI) 4.59 ± 0.14 4.41 ± 0.20 7.51 ± 0.27** 5.56 ± 0.27* 6.30 ± 0.12** 4.63 ± 0.16
Heart weight/body weight (g/100 g) 0.34 ± 0.01 0.30 ± 0.02 0.34 ± 0.01 0.41 ± 0.02* 0.33 ± 0.01 0.32 ± 0.01
  1. 1Values are means ± SEM for nine rats. *p < 0.05 and **p < 0.001 by the Bonferroni t-test multiple comparisons versus control group (HC). HC = hypercholesterolemic diet; HC+7S = HC diet + β-conglycinin 300 mg/kg/day; HC+FF = HC diet + fenofibrate 30 mg/kg/day; HC+RO = HC diet + rosuvastatin 10 mg/kg/day; HC+7S+FF = HC diet + β-conglycinin + fenofibrate, 300 and 30 mg/kg/day respectively, and HC+7S+RO = HC diet + β-conglycinin + rosuvastatin, 300 and 10 mg/kg/day respectively. Hepatossomatic índex (HI) = liver weight/body weight × 100.